To provide IGF-I and insulin variants selectively bonding to IGFBP-1 (IGF bonding protein-1) and IGFBP-3.
The IGF-I variant comprises natural sequence human IGF-1 whose amino acid are substituted at a position of 3, 4, 5, 6, 7, 10, 14, 17, 23, 24, 25, 43, 49 or 63, substituted at the position and at position(s) 12 or 16 or both of 12 and 16 combinedly, or substituted at optional combinations thereof, with (i) alanine or serine at position 3, (ii) serine at position 4, (iii) an optional amino acid at the above-mentioned position 7 and (iv) alanine or glycine at position 24 and alanine, glycine or serine residue at positions other than 3, 4, 7 and 24. The variants selectively bond to IGFBP-1 and IGFBP-3. For instance, these agonist variants increase half-lives of IGF-I and insulin, respectively.
LOWMAN HENRY (US)
Kobayashi Yoshinori